Preventing Anthracycline-Induced Cardiotoxicity Using Functional Genomics and Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Valentina Lo Sardo^{1

2}, Timothy J Kamp^{1

2

3}

Affiliations

¹ Department of Cell and Regenerative Biology (V.LS., T.J.K.), University of Wisconsin-Madison.
² Stem Cell and Regenerative Medicine Center (V.LS., T.J.K.), University of Wisconsin-Madison.
³ Department of Medicine (T.J.K.), University of Wisconsin-Madison.

Editorial

Valentina Lo Sardo et al. Circulation. 2022.

. 2022 Jan 25;145(4):295-298.

doi: 10.1161/CIRCULATIONAHA.121.058128. Epub 2022 Jan 24.

Valentina Lo Sardo^{1

2}, Timothy J Kamp^{1

2

3}

¹ Department of Cell and Regenerative Biology (V.LS., T.J.K.), University of Wisconsin-Madison.
² Stem Cell and Regenerative Medicine Center (V.LS., T.J.K.), University of Wisconsin-Madison.
³ Department of Medicine (T.J.K.), University of Wisconsin-Madison.

No abstract available

Keywords: Editorials; anthracyclines; doxorubicin; genetic loci; induced pluripotent stem cells; myocytes, cardiac.

Comment on

Identification of Drug Transporter Genomic Variants and Inhibitors That Protect Against Doxorubicin-Induced Cardiotoxicity.
Magdy T, Jouni M, Kuo HH, Weddle CJ, Lyra-Leite D, Fonoudi H, Romero-Tejeda M, Gharib M, Javed H, Fajardo G, Ross CJD, Carleton BC, Bernstein D, Burridge PW. Magdy T, et al. Circulation. 2022 Jan 25;145(4):279-294. doi: 10.1161/CIRCULATIONAHA.121.055801. Epub 2021 Dec 7. Circulation. 2022. PMID: 34874743 Free PMC article.